Suzhou Suncadia Biopharmaceuticals Co., Ltd.

This study tests a new drug called SHR-8068 combined with other cancer treatments for people with colorectal cancer. The goal is to see if the combination is safe and helps shrink tumors or slow cancer growth. About 200 adults aged 18 to 75 will take part, and they must provide t…

This trial tests whether an investigational drug called SHR-1314 can reduce joint pain, swelling, and skin symptoms in adults with active psoriatic arthritis. Participants receive either SHR-1314 or a placebo injection over 24 weeks, with follow-up for safety. The study aims to s…

This early-phase trial is testing an experimental drug called SHR-A2009 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The main goals are to find a safe dose and to understand the drug's side effects and how t…

This early-stage trial tests an experimental drug called SHR-1316, given as a shot under the skin, together with standard chemotherapy (carboplatin and etoposide) in people with extensive-stage small cell lung cancer who have not had prior treatment. The study looks at how the dr…

This study tests a new drug combination for people with advanced biliary tract cancer (bile duct cancer) who haven't had treatment before. About 93 participants will receive either a standard chemotherapy plus two immunotherapy drugs, or the same plus an extra experimental drug. …

This study was designed to test a new combination of drugs for people with advanced non-small cell lung cancer. The goal was to see if the treatment was safe and could shrink tumors. However, the trial was withdrawn before any participants were enrolled, so no results are availab…

This Phase 3 study compares a new experimental drug, SHR-A2009, to standard chemotherapy in 498 people with advanced EGFR-mutated non-small cell lung cancer whose current targeted therapy (EGFR TKI) has stopped working. The goal is to see if SHR-A2009 can better control the cance…

This Phase 2 trial tests whether adding an experimental immunotherapy drug (SHR-8068) to a standard immunotherapy (adebrelimab) plus chemotherapy can shrink tumors better than standard treatment alone in people with advanced stomach or esophageal cancer. About 153 participants wi…